BioMarin Pharmaceutical's total assets for Q4 2024 were $6.99B, an increase of 2.01% from the previous quarter. BMRN total liabilities were $1.33B for the fiscal quarter, a -7.43% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.